Skip to main content

Find a clinical trial

Find a clinical trial

Trial status
Trial Phase
Trial type
204 clinical trials grid list download
  • Titre Organe Phase Statut Crittères majeurs d'inclusion Contact
  • 1206 - HNCG A randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs) Cavité buccale et lèvres phase 2 Fermé metastatic, RECIST 1.1 Yassine Lalami
  • 1301-LG 10-day decitabine versus conventional chemotherapy (?3+7?) followed by allografting in AML patients >= 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group Leucémie aigüe phase 3 Ouvert 1st line / Eligible for standard intensive chemotherapy/ De novo or secondary AML is allowed Dominique Bron
  • 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Tumeur maligne phase 1 Ouvert any line, RECIST 1.1 Ahmad Hussein Awada
  • 1407 GUCC TIGER A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors Testicules phase 3 Ouvert Germ cell tumor Thierry Gil
  • 38RC17.290 Characteristics and Care of Solid Tumor Patients Treated With Immunotherapy Admitted in Intensive Care Unit. Tumeurs solides Fermé Treatment by Immunotherapy <6monthsAdmission in intensive care Anne-Pascale Meert
  • 8951-CL-0301 A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Estomac - Jonction duodénum-oesogastrique phase 3 Ouvert Unresecable or metastatic Amelie Deleporte
  • AB11002 AB11002 A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib to sunitinib in patients with gastrointestinla stromal tumor after progression with imatinib. Estomac - Jonction duodénum-oesogastrique phase 3 Fermé c-Kit positive. Progression under imatinib Thierry Gil
  • ADRIATIC A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC) Poumon phase 3 Ouvert 4 lines chemotherapy and radiation Bogdan Grigoriu
  • AG013-ODOM-201 A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy Tête et Cou phase 2 Fermé No prior gene therapy Dirk Van Gestel
  • AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiples phase 1/1b Ouvert any line, RECIST 1.1 Philippe Aftimos
  • AMG420 -20160370 A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma phase 1/2 Fermé Nathalie Meuleman
  • AMG510 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation Multiples phase 1/2 Ouvert Locally-advanced or metastatic malignancy with : KRAS p.G12Cmutation Nuria Kotecki
  • ANAM-17-21 A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced nonsmall cell lung cancer (NSCLC) NSCLC phase 3 Ouvert Ongoing problemn with apetite/eating. Maximum 3 lines of systemic prior Thierry Berghmans
  • ANDROMEDA A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis Amyloidose phase 3 Ouvert Histopathological diagnosis of amyloidosis based on detection by IHC and polarizing light microscopy of green bi-refringent material in congo red-stained tissue specimens (in an organ other than bone marrow) or characteristic electron microscopy appearanc Nathalie Meuleman